Navigation Links
High Levels of Protein Linked to Brain Shrinkage

h is needed to prove that high homocysteine levels lead to brain atrophy. He pointed out that homocysteine levels did not predict how well participants performed on tests of mental ability.

"If there was indeed increased brain atrophy, it was not severe enough in this otherwise healthy group to significantly impact on functioning," he said. Although Sachdev noted that more research is needed, he said that the current scientific evidence is "persuasive enough for a public awareness campaign about homocysteine levels, especially in those at risk for coronary artery disease, stroke and dementia."

He noted that folic acid supplements can return homocysteine levels to normal. The studies "provide important leads but no proof" that high homocysteine levels lead to mental decline, according to an accompanying editorial by Dr. James F. Toole of Wake Forest University in Winston-Salem, North Carolina, and Dr. Clifford R. Jack of the Mayo Clinic in Rochester, Minnesota.

Still, the research is "exciting," Toole said in a news release, since it is possible to lower homocysteine levels with vitamins B6, B12 and folic acid. Toole is currently investigating whether these supplements can reduce the risk of stroke. Another important area of research, according to Toole, is to see whether lowering homocysteine with vitamins will prevent Alzheimer's and other forms of dementia.


'"/>




Page: 1 2

Related medicine news :

1. Levels Of Blood Proteins May Help Heart Disease Care
2. Elevated Ozone Levels Hurt Sperm Count
3. Elevating Manganese Levels hold back HIV
4. Chickens Found To Have High Levels of Arsenic
5. Low Protein Levels A Possible Indicator For A Miscarriage
6. Low Testosterone Levels the Cause Of Depression In Men
7. Weather Found To Play An Important Role In Cholesterol Levels
8. Education Levels Found To Predict Stress
9. Effective Control Of Blood Sugar Levels
10. Elevated Blood Sugar Levels A Risk Factor Of Heart Disease
11. Better Control Of Sugar Levels
Post Your Comments:
(Date:10/10/2008)...LE, PA The American Nurses Credentialing Center (...) as a Magnet hospital. The news came via a confer...taff who broke out with cheers and applause., GMC...itals and only 294 hospitals in the United States... hospitals are eligible for this recognition., "A...
(Date:10/10/2008)...ggests poor self-care partly to blame , ,...f Medicare beneficiaries who have diabetes, being ... according to a new study. , Publishing in th...l Medicine , researchers from the University of Wa...erage age of 75.6 years) who had diabetes and were...
(Date:10/10/2008)... Honoring excellence in the imple... Healthcare Information and Management Systems Soc...Davies Awards in the Organizational, Ambulatory an... Chicago, IL (PRWEB) October 1...on of electronic health records (EHRs), the Healt...
(Date:10/10/2008)...YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins Un...ultimedia educational program,"Optimizing Adjuvan...atment,Selection," to present recent key research ...ment., In recent years, advancements in the treat... and biologic treatment combinations that are,incr...
Breaking Medicine News(10 mins):Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2
...rcises can help restore erectile function in men, ...the University of the West of England in Bristol f...floor exercises had the same overall improvement a...elvic floor is made up of layers of muscle and oth...
...ered a gene mutation that may cause premature ovar...be useful for further study into, what researchers...ovarian failure is a form of infertility that affe...es. It is diagnosed in one out of every 100 women ...
...d allergy -- especially to peanuts -- has been sho...in children. Asthma attacks are the most common re...am Roberts from St. Mary's Hospital in London and ...n treatment, death due to childhood asthma has not...
...lacement therapy dosed to normalize IGF-I levels m...on in a "clinically necessary" weight loss program...ograms is to lose body fat but retain lean body ma... when people go on a diet, after a while, they sto...
Other Medicine News:Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2
(Date:10/8/2008)...view Zanolimumab Program to be Discontinued and He...he Results of its Portfolio Review; Zanolimumab P...uce the Number of Em...all/ -- Genmab A/S (OMX: GEN),announced today that...uMax-CD4(R)). In addition, as a result of a portfo...
(Date:10/8/2008)...SEUS clinical program to evaluate TAXUS(R) Element... Stent, NATICK, Mass., Oct. 8 /PRNewswire-Fir...SX ) today announced that it has completed enrollm... Company,s third-generation,TAXUS(R) Element(TM) p...ical program has enrolled nearly 1,500 patients at...
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical Incorp...ed clinical data and new nonclinical data,demonstr... be broadly,applicable in DNA- and protein-based i...r vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vic... will present the data today,Wednesday, October 8...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Labo... today announced findings from its,development of ...lood test,for irritable bowel syndrome (IBS). The ...ression of particular biomarkers in blood samples,...on of these biomarkers,combined with a proprietar...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Cancer cell line developed that is resistant to new cancer therapy 8043 1Cancer cell line developed that is resistant to new cancer therapy 8043 2New carbon calculator conserves forests 1542 1New carbon calculator conserves forests 1542 2Young Physicians Demanding Advanced Laparoscopic Energy Instruments 2130 1Young Physicians Demanding Advanced Laparoscopic Energy Instruments 2130 2Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference 2128 1Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference 2128 2
...inal Results from Exploratory Phase IIa Clinical T...O, June 28, 2007 /PRNewswire-FirstCall/ - Transiti...ces the results from,its exploratory Phase IIa cli...ments with gastrin-based therapy, E1-I.N.T.(TM), s...l parameters, including,haemoglobinA1C (HbA1c), fo...
...MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytochro... I clinical trial of,CTA018 Injection. The initial...18 was safe and well tolerated. Complete study,res...ompleted Phase I trial was an open label,placebo-...dministered to 20 healthy volunteers. In this tria...
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3
Heavy. 7.5 mm curved tip.
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1.
Size 4 - 2.25 mm
The Catalyst system introduces a new level of computer enhanced precision to microsurgical instrumentation. It has an easy to use digital design with advanced microcomputer control of modules and is
Medicine Products: